Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPOS trial of pirfenidone for bronchiolitis obliterans syndrome after double lung transplantation
NL-OMON47103Phase 2Active, not recruiting
- Sponsor
- Rigshospitalet
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Bronchiolitis Obliterans Syndrome (BOS) comparing Pirfenidone plus azithromycin with Placebo plus azithromycin (2 arms). Primary endpoint: Change in FEV1 at 6 months. Started Jan 2017; status: active, not recruiting.
02
Drugs
pirfenidone
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NL-OMON47103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47103.